CAMBRIDGE, UK, April 27, 2026

AstraZeneca has received U.S. Food and Drug Administration (FDA) approval for the subcutaneous self-administration of Saphnelo® (anifrolumab) via a new autoinjector, marking a significant advancement in the treatment of systemic lupus erythematosus (SLE). The newly approved Saphnelo Pen enables once-weekly self-administration, offering patients greater flexibility, convenience, and improved access to therapy outside clinical settings. This milestone reflects a major step forward in patient-centric drug delivery innovation, expanding treatment options for individuals living with moderate to severe autoimmune disease.

FDA Approval Backed by Strong Phase III Clinical Data

The FDA approval is supported by robust results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous administration of Saphnelo significantly reduced disease activity compared to placebo in patients receiving standard therapy. The trial confirmed clinically meaningful improvements across multiple endpoints, including reduced disease severity, faster response rates, and delayed disease flares. Importantly, the safety profile of the subcutaneous formulation remained consistent with the established intravenous (IV) formulation, reinforcing confidence in its clinical use.

Saphnelo, a first-in-class monoclonal antibody targeting the type I interferon receptor, works by blocking inflammatory pathways central to SLE pathogenesis, addressing a key underlying driver of the disease rather than just managing symptoms. The study also highlighted that a significant proportion of patients achieved low disease activity and remission benchmarks, supporting its role as a transformative therapy in lupus management.

Innovative Science Driving Next-Generation Therapies

Advertisement

cGxPJobs Banner

AJ1-11095 is designed to overcome key limitations of existing therapies by targeting resistance mechanisms in JAK2 signaling, a critical pathway in MPNs such as myelofibrosis and polycythemia vera. Current treatments, while effective in symptom control, often fail to deliver sustained benefits, leading to discontinuation in many patients. The novel binding approach of AJ1-11095 could provide a new therapeutic option for patients who have exhausted existing JAK inhibitor treatments, addressing a significant unmet medical need.

The drug is administered as a once-daily oral therapy, enhancing patient convenience and adherence while maintaining strong efficacy potential. The ongoing Phase 1 study, initiated in late 2024, is expected to determine optimal dosing for future trials, marking a critical step in its clinical development pathway.

Advancing Patient-Centric Treatment in Autoimmune Disease

The introduction of the Saphnelo Pen represents a major shift toward more accessible and convenient treatment options, allowing patients to administer therapy at home rather than relying solely on hospital-based IV infusions. This innovation is particularly impactful for individuals with chronic conditions like SLE, where long-term treatment adherence and quality of life are critical considerations.

Systemic lupus erythematosus is a complex autoimmune disease affecting over 3.4 million people worldwide, often leading to severe organ damage, chronic pain, and reduced quality of life. Traditional treatments, including corticosteroids, are associated with significant side effects and do not target the underlying disease mechanisms. Saphnelo offers a targeted biologic approach, reducing reliance on steroids while improving disease control, aligning with modern treatment guidelines that emphasize remission and minimized long-term toxicity.

Global Expansion and Lifecycle Innovation

The approval of the subcutaneous formulation further strengthens AstraZeneca’s lifecycle management strategy for Saphnelo, which is already approved in more than 70 countries as an intravenous therapy. With over 40,000 patients treated globally, the addition of an autoinjector format broadens the drug’s reach and enhances its commercial and clinical potential.

Subcutaneous Saphnelo has already been approved in regions such as the EU and Japan, and ongoing regulatory reviews in additional markets signal continued global expansion. Furthermore, the therapy is being investigated in multiple autoimmune indications, including lupus nephritis, systemic sclerosis, and myositis, highlighting its broader potential in immune-mediated diseases.

From a cGxP perspective, this approval underscores the importance of integrating clinical evidence, regulatory compliance, and innovative drug delivery systems to enhance patient outcomes, while maintaining stringent quality and safety standards throughout the product lifecycle.

Source: AstraZeneca press release